AstraZenecas Imfinzi Gets FDA Nod for Expanded Use in SCLC
The FDA approves AZNs Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC study data.…
62,500€
-7,75%
Echtzeit-Aktienkurs ASTRAZENECA DL-,25 SP.ADR
Bid:
Ask:
Nachrichten zur ASTRAZENECA DL-,25 SP.ADR Aktie
Erkrankung nach Corona-Impfung - Gericht fordert Gutachten
BAMBERG (dpa-AFX) - Im Prozess gegen den Pharmakonzern Astrazeneca um einen möglichen Corona-Impfschaden hat eine Frau aus Oberfranken einen…
AstraZeneca appoints Iskra Reic EVP International
4 December 2024
AstraZeneca appoints Iskra Reic as Executive Vice President, International
AstraZeneca today announced the appointment of Iskra Reic as Executive…
FTSE 100 on its own in the red as AstraZeneca slumps, L&G surges on annuity boost
FTSE 100 drops 18 points London stock market exodus worsens Rio Tinto faces activist pressure 4.05pm: FTSE still on its…
FTSE 100 Live: AstraZeneca leads decline, L&G surges, Wall Street opens higher
FTSE 100 drops 14 points London stock market exodus worsens Rio Tinto faces activist pressure 2..49pm: Wall Street opens higher…
FTSE 100 Live: AstraZeneca leads decline, L&G surges on annuity update
FTSE 100 drops 30 points European markets higher, ahead of French no-confidence vote Rio Tinto faces activist pressure 10.04am: Festive petrol…
FTSE 100 rally gathers momentum as heavyweights lift index
The FTSE 100 soared on Tuesday in a broad rally driven by London’s heavyweight stocks including Shell, AstraZeneca, and HSBC.…
Novo Nordisk and AstraZeneca top of the 2025 drug picks for US investment bank
Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan’s latest…
Novo Nordisk and AstraZeneca top 2025 drug picks for US investment bank
Success in 2025 for the pharma sector will hinge on the success of key drug pipeline developments, according to JPMorgan’s latest…
AstraZeneca Overweight
NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Astrazeneca mit einem Kursziel von 14000 Pence auf "Overweight" belassen. Das…